Image

North America Topical Drug Delivery Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

North America Topical Drug Delivery Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Feb 2023
  • North America
  • 350 Pages
  • No of Tables: 195
  • No of Figures: 55

North America Topical Drug Delivery Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD 80,484.97
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Topical Drug Delivery Market, Product Type (Drug Delivery Formulations and Drug Delivery Devices), Delivery Techniques (Ionotophoresis, Sonophoresis, Laser Ablation, Radio Frequency Ablation, Magnetophoresis, Electroporation And Others), Type (Cleansing Agents, Protective Agents, Moisturizing Agents, Drying Agents, Anti-Itch Agents, Anti-Inflammatory Agents, Anti-Infective Agents, Keratolytics, and Others), Generation (First Generation Transdermal Delivery Systems, Second Generation Transdermal Delivery Systems and Third Generation Transdermal Delivery Systems), Mode of Purchase (Prescription and Over The Counter), Indication (Dermatological Disorders, Ophthalmic Disorders, Pain Management, Neurosurgical Disorders, Hormonal Therapy, Smoking Cessation and Others), Route of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal and Others), End User (Hospitals, Specialty Centers, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2030.

North America Topical Drug Delivery Market

North America Topical Drug Delivery Market Analysis and Insights

North America topical drug delivery market is increasing with the rising prevalence of skin disorders and ophthalmic disorders in North America. Further, rising spending on healthcare and growing awareness for diagnostics and skin disease treatment are also contributing to market value growth. Thus. Increasing the demand for dermatology prescription-based drugs. Increasing research and development in topical drug delivery is creating new opportunities in the topical drug delivery market.

North America Topical Drug Delivery Market

North America Topical Drug Delivery Market

Data Bridge Market Research analyzes that the North America topical drug delivery market is expected to reach the value of USD 80,484.97 million by 2030, at a CAGR of 6.8% during the forecast period Increasing the demand for dermatology prescription-based drugs. Increasing research and development in topical drug delivery is creating new opportunities in the topical drug delivery market. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2015)

Quantitative Units

Revenue in Million, Pricing in USD

Segments Covered

Product Type (Drug Delivery Formulations and Drug Delivery Devices), Delivery Techniques (Ionotophoresis, Sonophoresis, Laser Ablation, Radio Frequency Ablation, Magnetophoresis, Electroporation And Others), Type (Cleansing Agents, Protective Agents, Moisturizing Agents, Drying Agents, Anti-Itch Agents, Anti-Inflammatory Agents, Anti-Infective Agents, Keratolytics, and Others), Generation (First Generation Transdermal Delivery Systems, Second Generation Transdermal Delivery Systems and Third Generation Transdermal Delivery Systems), Mode of Purchase (Prescription and Over The Counter), Indication (Dermatological Disorders, Ophthalmic Disorders, Pain Management, Neurosurgical Disorders, Hormonal Therapy, Smoking Cessation and Others), Route of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal and Others), End User (Hospitals, Specialty Centers, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

CRESCITA THERAPEUTICS INC., Cipla Inc., Glenmark, Bausch Health Companies, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Viatris Inc., NITTO DENKO CORPORATION, LTS Lohmann Therapy Systems AG, Procter & Gamble, ANI Pharmaceuticals, Inc., Corium, Inc., Medherant Limited., Purdue Pharmaceuticals L.P., AbbVie Inc., GSK plc., 3M., Agile Therapeutics, Tapemark, tesa Labtec GmbH, Noven Pharmaceuticals, Inc. among others

Market Definition

Topical drug delivery is considered one of the most effective methods due to its optimal therapeutic benefits. The desired therapeutic effect and unwanted side effect of a drug are both determined by the concentration of the drug at the site of action. The concentration of the drug is determined by the dosage form and absorption of the drug at the site of action. The growth of this market is attributed to the rising prevalence of diabetes, the growing number of burn cases, escalating prevalence of dermal diseases, and technological developments in topical drug delivery systems. In addition, the major consumers of topical drug delivery systems are specialty clinics and hospitals. Some other consumers include diagnostic centers and home care centers.

North America Topical Drug Delivery Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • HIGH PREVALENCE OF SKIN DISEASES

The prevalence of skin diseases is expanding at a quicker rate, and it is becoming a North America problem. The enormous burden of various skin diseases and conditions makes drug administration crucial. The increased prevalence of skin conditions positively impacts the North America topical drug delivery market. As a result, the market is estimated to show lucrative growth over the forecasted period. The increasing incidences of skin infections such as eczema, psoriasis, and minor ailments, including acne, are the most significant factors driving the growth of this market.

  • RISING COMPANY ACTIVITIES IN DEVELOPING PRODUCTS AND INCREASING PRODUCT LAUNCHES

As various skin diseases are on the urge, the need for topical drugs is rapidly increasing. Various companies are taking initiatives to develop new products and launch them in the market. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market.

  • HIGH INCIDENCE OF BURN INJURIES

Burns are tissue damage that results from heat, overexposure to the sun or other radiation, or chemical or electrical contact. Burns can be minor medical problems or life-threatening emergencies. High incidences of burn injuries are seen in various regions across the globe.

Restraints

continuous irritation on THE skin and allergies caused by topical drugs

Many topical formulations are available over the counter, including antibacterial and antifungal preparations, anti-inflammatory and pain relief preparations, and cleansing and moisturizing agents. Topical corticosteroids are used in many inflammatory rashes. However, in some cases, topical corticosteroid sensitivity produces allergic reactions.

Usually, this is seen as a failure to cure dermatitis or to worsen existing dermatitis treated with corticosteroids. Very rarely, corticosteroid allergy may appear as an eczematous rash in a completely different area of the body from original dermatitis.

Some topical antibodies may also cause contact allergies, such as bacitracin, which is used to prevent minor skin injuries such as cuts, scrapes, and burns. Benzocaine and salicylate are some active ingredients in topical formulations which causes allergies. These allergies caused by such drugs can be diagnosed by a patch test that can detect contact allergens.

discontinued product recalls in the u.s.

Product recall is the most common threat for any business or any market. It has a serious negative impact on the market, such as decreased market size and a decline in revenue for the company, among others. In the topical drugs market, various products are recalled due to some defect in batch or after getting banned by the FDA.

North America Topical Drug Delivery Market

Opportunity

Extensive R&D activities in dermatology drugs

 Rising R&D activities for developing innovative and highly efficient drugs are expected to boost market growth. There is a rising demand for therapies and a deeper understanding of disease pathways, genetic discoveries, antibody drug development, novel targets, advanced delivery technologies, and diagnostic technologies which can be utilized in translational research and clinic.

The increase in the burden of skin-related diseases with unmet medical needs has increased the demand for new innovative drugs for treating infectious skin diseases, pigmentation disorders, and inflammatory/autoimmune disorders, which has increased the research and development activities for dermatological drugs in order to bring new drugs to market.

Challenge

Stringent Regulation for product approval

Regulation of drugs and topical ointments plays a significant role in healthcare. Achieving the requisite approval for legal selling medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or considered, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, among others, are of significant importance for treating various diseases. But their approval and marketing in multiple regions across North America require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.

Post-COVID-19 Impact on North America Topical Drug Delivery Market

The pharmaceutical industry has been severely affected by the COVID-19 pandemic. Lockdowns imposed due to the epidemic have disrupted the supply of raw materials from manufacturing centers such as India and China. This slowed drug development and production, severely affecting companies that relied heavily on outsourcing. Initially, the entire pharmaceutical ecosystem was disrupted. In addition, regulatory agencies had to draft and draft new laws to ensure maximum patient safety after using drugs. After the shutdowns ended, the pharmaceutical industry gained steam, especially due to the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The growing demand for these drugs boosted the turnover of some companies.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology in the topical drug delivery market.

Recent Developments

  • In December 2022, GSK plc announced new 48-week data from the MOMENTUM phase III trial were released, showing that most patients treated with investigational momelotinib maintained their responses across critical clinical measures, such as the Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR), in myelofibrosis patients who had previously received treatment with an approved Janus kinase (JAK) inhibitor. In addition, fresh MOMENTUM studies revealed that the TI response to momelotinib at week 24 was related to overall survival. This has helped the company to expand its business in the market
  • In January 2022, Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced a new alliance with Afaxys Pharma, LLC to promote Twirla (levonorgestrel and ethinyl estradiol) transdermal system. This has helped the company to increase its North America presence in the market

North America Topical Drug Delivery Market Scope

North America topical drug delivery market is segmented into product type, delivery technique, type, generation, mode of purchase, indication, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

North America Topical Drug Delivery Market, By Product Type

  • Drug Delivery Formulations
  • Drug Delivery Devices

On the basis of product type, the North America laboratory hoods and enclosure market is segmented into drug delivery formulations and drug delivery devices.

North America Topical Drug Delivery Market, By Delivery Techniques

  • Sonophoresis
  • Electroporation
  • Laser Ablation
  • Ionotophoresis
  • Radio Frequency Ablation
  • Magnetophoresis
  • Others

On the basis of delivery techniques, the North America laboratory hoods and enclosure market is segmented into ionotophoresis, sonophoresis, laser ablation, radio frequency ablation, magnetophoresis, electroporation and others.

North America Topical Drug Delivery Market, By Type

  • Cleansing Agents
  • Protective Agents
  • Moisturizing Agents (Emollients)
  • Drying Agents
  • Anti-Itch Agents
  • Anti-Inflammatory Agents
  • Anti-Infective Agents
  • Kerolytics
  • Others

On the basis of type, the North America laboratory hoods and enclosure market is segmented into cleansing agents, protective agents, moisturizing agents, drying agents, anti-itch agents, anti-inflammatory agents, anti-infective agents, keratolytics, and others.

North America Topical Drug Delivery Market, By Generation

  • First-Generation Transdermal Delivery Systems
  • Second-Generation Transdermal Delivery Systems
  • Third-Generation Transdermal Delivery Systems

On the basis of generation, the North America laboratory hoods and enclosure market is segmented into first generation transdermal delivery systems, second generation transdermal delivery systems and third generation transdermal delivery systems.

North America Topical Drug Delivery Market, By Mode of Purchase

  • Prescription
  • Over The Counter

On the basis of mode of purchase, the North America laboratory hoods and enclosure market is segmented into prescription and over the counter.

North America Topical Drug Delivery Market, By Indication

  • Dermatological Disorders
  • Ophthalmic Disorders
  • Pain Management
  • Neurological Disorders
  • Hormonal Therapy
  • Smoking Cessation
  • Others

On the basis of indication, the North America laboratory hoods and enclosure market is segmented into dermatological disorders, ophthalmic disorders, pain management, neurosurgical disorders, hormonal therapy, smoking cessation and others.

North America Topical Drug Delivery Market, By Route Of Administration

  • Dermal
  • Ophthalmic
  • Rectal
  • Vaginal
  • Nasal
  • Others

On the basis of route of administration, the North America laboratory hoods and enclosure market is segmented into dermal, ophthalmic, rectal, vaginal, nasal and others.

North America Topical Drug Delivery Market, By End User

  • Hospitals
  • Home Healthcare
  • Specialty Centers
  •  Others

On the basis of end user, the North America laboratory hoods and enclosure market is segmented into hospitals, specialty centers, home healthcare, and others.

North America Topical Drug Delivery Market, By Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the North America laboratory hoods and enclosure market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.

North America Topical Drug Delivery Market

North America Topical Drug Delivery Market Regional Analysis/Insights

North America topical drug delivery market is analyzed, and market size information is provided product type, delivery technique, type, generation, mode of purchase, indication, route of administration, end user, and distribution channel.

Some countries covered in this market report are U.S., Canada, and Mexico.

North America is expected to dominate due to the presence of key market players in the largest consumer market with high GDP. The U.S is expected to grow due to the rise in technological advancement in Healthcare IT.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Topical Drug Delivery Market Share Analysis

North America topical drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus on the North America topical drug delivery market.

Some of the major players operating in the North America topical drug delivery market are CRESCITA THERAPEUTICS INC., Cipla Inc., Glenmark, Bausch Health Companies, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Viatris Inc., NITTO DENKO CORPORATION, LTS Lohmann Therapy Systems AG, Procter & Gamble, ANI Pharmaceuticals, Inc., Corium, Inc., Medherant Limited., Purdue Pharmaceuticals L.P., AbbVie Inc., GSK plc., 3M., Agile Therapeutics, Tapemark, tesa Labtec GmbH, Noven Pharmaceuticals, Inc. among others.


SKU-

TABLE 1 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 6 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 8 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 10 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 12 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA DRUG IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA NEXT GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA MINIMALLY INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA VAPOR PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 43 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 45 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 46 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 48 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 50 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 76 U.S. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 77 U.S. DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 78 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 80 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 81 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 83 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 84 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 86 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 87 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 89 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 90 U.S. TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 U.S. PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 U.S. RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 93 U.S. MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 94 U.S. DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 95 U.S. NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 96 U.S. ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 U.S. MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 U.S. VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 99 U.S. TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)

TABLE 100 U.S. TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 101 U.S. ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 102 U.S. ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 103 U.S. ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 104 U.S. TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 105 U.S. TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 106 U.S. NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 107 U.S. KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 108 U.S. TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)

TABLE 109 U.S. TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 110 U.S. TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 111 U.S. DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 112 U.S. OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 113 U.S. TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 114 U.S. TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 U.S. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 116 CANADA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 117 CANADA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 120 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 121 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 122 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 123 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 124 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 126 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 127 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 129 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 130 CANADA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 CANADA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 CANADA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 133 CANADA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 134 CANADA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 CANADA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 136 CANADA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 137 CANADA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 138 CANADA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 139 CANADA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)

TABLE 140 CANADA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 141 CANADA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 142 CANADA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 143 CANADA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 144 CANADA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 CANADA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 146 CANADA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 147 CANADA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 148 CANADA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)

TABLE 149 CANADA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 150 CANADA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 151 CANADA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 152 CANADA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 153 CANADA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 154 CANADA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 155 CANADA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 MEXICO TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 157 MEXICO DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 158 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 159 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 160 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 161 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 163 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 164 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 166 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 167 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 168 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)

TABLE 169 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 170 MEXICO TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 171 MEXICO PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 172 MEXICO RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 173 MEXICO MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 174 MEXICO DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 175 MEXICO NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 176 MEXICO ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 177 MEXICO MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 178 MEXICO VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 179 MEXICO TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)

TABLE 180 MEXICO TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 181 MEXICO ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 182 MEXICO ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 183 MEXICO ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 184 MEXICO TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 185 MEXICO TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 186 MEXICO NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 187 MEXICO KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 188 MEXICO TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)

TABLE 189 MEXICO TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 190 MEXICO TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 191 MEXICO DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 192 MEXICO OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 193 MEXICO TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 194 MEXICO TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 195 MEXICO TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America Topical Drug Delivery Market is projected to grow at a CAGR of 6.8% during the forecast period by 2030.
The future market value of the North America Topical Drug Delivery Market is expected to reach USD 80,484.97 million by 2030.
The major players in the North America Topical Drug Delivery Market are CRESCITA THERAPEUTICS INC., Cipla Inc., Glenmark, Bausch Health Companies, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., etc.
The countries covered in the North America Topical Drug Delivery Market are U.S., Canada, Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials